A growing body of evidence suggests that drug and target interactions occur within a complex and intricate network of biological effects. Therefore, a network approach to the study of human disease and drug-therapy interactions is needed to improve the productivity and efficiency of drug development. Nodality's proprietary Single Cell Network Profiling (SCNP) technology provides a comprehensive analysis of the biological network underlying specific diseases and the changes caused by stimuli such as therapeutics. Using the MyProfile™ approach, Nodality collaborates with pharmaceutical and biotechnology companies to improve and accelerate drug development.
SCNP can enhance and accelerate pre-clinical and clinical development as well as the commercialization of novel therapeutics. Potential benefits include:
| Novel Characteristic | Differentiating Advantage | |
| 1. Pathway activation state characterization |  |
New level of information that reveals therapeutic efficacy |
| 2. Single cell resolution | |
Insight into cell population, and therefore disease heterogeneity |
| 3. Functional pathway dynamics | |
Systems biology approach to reveal disease phenotype vs genotype |
| 4. Standardized, quantitative methodology | |
Meets standards for drug development and regulatory submissions |
| 5. Longitudinal measurements | |
Enables study of individual patients over time: insight into evolution and mechanisms of resistance |
| 6. Extensive IP Portfolio | |
Proprietary platform, technology, use, and commercialization |